Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Biovitrum AB acquires the pharmaceutical company Arexis AB
Mandate

Biovitrum AB acquires the pharmaceutical company Arexis AB

October 03, 2005

Biovitrum, a Swedish biotech company, acquires Arexis, a privately owned Swedish biotech and pharmaceuticals company, for an undisclosed consideration, from 3i Group Plc, Beijer Investors, Industrifonden, InnovationsKapital, and SEB Företagsinvest.

Vinge acted for Biovitrum AB.
Michael Wigge (responsible partner)
Niclas Bergström (associate)

Related

Vinge advises Axcel and Accru Partners in connection with the acquisitions of Carlstedt & Lindh AB and Brahe Revisionsbyrå AB

 Vinge has advised Axcel VII and Accru Partners in connection with the acquisitions of Carlstedt & Lindh AB and Brahe Revisionsbyrå AB
April 24, 2025

Vinge advises Biotage in connection with RWK Bidco’s public tender

On 22 April 2025, RWK Bidco AB, a newly formed company indirectly wholly owned by KKR Funds, announced a public tender offer to the shareholders in Biotage AB to tender all ordinary shares in Biotage to RWK Bidco at a price of SEK 145 in cash per ordinary share.
April 22, 2025

Vinge advises Baseload Capital in connection with an investment from Google

 Vinge has advised Baseload Capital Holding AB in connection with securing an investment from Google.
April 16, 2025